3 Top Growth Stocks Trading Below $5 to Buy This October

Investors looking for lower-priced stocks can buy shares of Columbia Care, HIVE Blockchain and 4Front Ventures right now.

| More on:
Knowledge concept with quote written on wooden blocks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Investing in lower-priced growth stocks remains an attractive option, as it allows portfolio diversification with a small amount of capital. For example, instead of buying one share of Amazon for over $4,000, you can purchase shares of several companies trading below $5. While this strategy carries significant risks, it also allows investors to generate stellar gains over time. Here, we take a look at three such growth stocks that Canadians can look to buy this month.

4Front Ventures

A U.S.-based cannabis stock flying under the radar, 4Front Ventures (CNSX:FFNT) is a small-cap company valued at $753 million. It has increased sales from US$4 million in 2018 to US$57.63 million in 2020. Analysts expect sales to rise by 271% year over year to US$213.8 million in 2021 and by 41.6% to US$303 million in 2022. The company’s adjusted earnings are also forecast to improve to US$0.16 per share in 2022 from a loss per share of US$0.08 in 2020.

In Q2 of 2021, 4Front Ventures revenue rose 85% year over year to US$34.4 million. Comparatively, adjusted EBITDA increased by 27% sequentially to US$7.5 million, indicating a margin of 22%.

4Front reiterated systemwide pro forma revenue of between US$170 million and US$180 million in fiscal 2021 with an adjusted EBITDA of between US$40 million and US$50 million. It emphasized that existing licensed projects at maturity represent a long-term revenue and EBITDA opportunity of over US$650 million and US$250 million respectively.

HIVE Blockchain

For investors bullish on the cryptocurrency space, HIVE Blockchain (TSXV:HIVE)(NASDAQ:HVBT) is a company that should be on your radar. Priced at $4.5 per share and valued at a market cap of $1.73 billion, HIVE stock is up a massive 4,620% since the start of 2020. So, a $1,000 investment in HIVE in January 2020 would be worth more than $47,000 today.

In the first quarter of fiscal 2021 ending in June, HIVE’s gross revenue from digital currency mining stood at $37.2 million, an increase of 466% year over year. It was also 11% higher on a sequential basis.

This allowed the company to report a net income of $18.6 million, up from just $1.8 million in the year-ago period. HIVE’s gross mining margin expanded to $31 million in Q2 from $2.6 million in the year-ago period. Investors should know that the stock price of crypto mining companies such as HIVE is closely related to the digital asset they mine, making the shares as volatile as their underlying assets.

Columbia Care

The final stock on my list is another cannabis company with a huge presence south of the border. Shares of Columbia Care (CNSX:CCHW) are priced at $4.34, valuing the company at a market cap of $1.58 billion. While the stock has gained over 70% in the last 18 months, it also traded 55% below all-time highs.

Analysts expect Columbia Care to increase sales by 248% to US$625 million in 2021 and by 55.4% to US$971 million in 2022. This rapid expansion in the top line will also allow the company to report adjusted earnings of US$0.3 in 2022 compared to a loss of US$0.48 in 2020.

It’s now one of the largest multi-state operators in the U.S., with 99 dispensaries and 31 cultivation facilities in the country. Columbia Care also has licenses to operate in 18 states where medical marijuana is legalized. Analysts expect shares of Columbia Care to more than triple over the next 12 months.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon. The Motley Fool recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »